Compare Stocks: CRMD, MLYS, HRMY, and RAPP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRMD CorMedix	$7.44 -0.9%	$8.22	$6.13 ▼ $14.96	$589.17M	1.5	877,128 shs	740,234 shs
HRMY Harmony Biosciences	$38.41 -0.9%	$35.19	$25.52 ▼ $40.87	$2.26B	0.96	944,184 shs	994,522 shs
MLYS Mineralys Therapeutics	$27.35 +1.3%	$26.49	$12.59 ▼ $47.65	$2.23B	0.68	638,792 shs	386,166 shs
RAPP Rapport Therapeutics	$45.49 -1.9%	$39.77	$13.86 ▼ $48.00	$2.22B	0.97	321,501 shs	246,056 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRMD CorMedix	-0.93%	-1.20%	-15.74%	-6.06%	-37.74%
HRMY Harmony Biosciences	-0.88%	+9.00%	+0.87%	+23.94%	+10.79%
MLYS Mineralys Therapeutics	+1.33%	+7.17%	-10.03%	-7.41%	+103.19%
RAPP Rapport Therapeutics	-1.86%	+11.01%	+8.34%	+19.58%	+211.36%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRMD CorMedix	$7.44 -0.9%	$8.22	$6.13 ▼ $14.96	$589.17M	1.5	877,128 shs	740,234 shs
HRMY Harmony Biosciences	$38.41 -0.9%	$35.19	$25.52 ▼ $40.87	$2.26B	0.96	944,184 shs	994,522 shs
MLYS Mineralys Therapeutics	$27.35 +1.3%	$26.49	$12.59 ▼ $47.65	$2.23B	0.68	638,792 shs	386,166 shs
RAPP Rapport Therapeutics	$45.49 -1.9%	$39.77	$13.86 ▼ $48.00	$2.22B	0.97	321,501 shs	246,056 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRMD CorMedix	-0.93%	-1.20%	-15.74%	-6.06%	-37.74%
HRMY Harmony Biosciences	-0.88%	+9.00%	+0.87%	+23.94%	+10.79%
MLYS Mineralys Therapeutics	+1.33%	+7.17%	-10.03%	-7.41%	+103.19%
RAPP Rapport Therapeutics	-1.86%	+11.01%	+8.34%	+19.58%	+211.36%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRMD CorMedix	2.75	Moderate Buy	$14.86	99.69% Upside
HRMY Harmony Biosciences	2.50	Moderate Buy	$45.50	18.46% Upside
MLYS Mineralys Therapeutics	2.63	Moderate Buy	$49.33	80.38% Upside
RAPP Rapport Therapeutics	2.92	Moderate Buy	$57.86	27.19% Upside

Current Analyst Ratings Breakdown

Latest CRMD, MLYS, HRMY, and RAPP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2026	HRMY Harmony Biosciences	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold	$39.00
8/5/2026	HRMY Harmony Biosciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$29.00 ➝ $34.00
8/5/2026	HRMY Harmony Biosciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$37.00
8/5/2026	RAPP Rapport Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
8/4/2026	HRMY Harmony Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$70.00
8/4/2026	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $50.00
7/31/2026	HRMY Harmony Biosciences	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$50.00 ➝ $51.00
7/28/2026	RAPP Rapport Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
7/17/2026	MLYS Mineralys Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	RAPP Rapport Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/16/2026	HRMY Harmony Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$55.00

(Data available from 8/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRMD CorMedix	$311.71M	1.87	$2.03 per share	3.67	$5.14 per share	1.45
HRMY Harmony Biosciences	$868.45M	2.58	$3.15 per share	12.19	$17.16 per share	2.24
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$8.17 per share	N/A
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	$8.81 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRMD CorMedix	$163.05M	$2.13	3.49	744.00	N/A	45.25%	45.57%	24.76%	8/13/2026 (Estimated)
HRMY Harmony Biosciences	$158.69M	$3.08	12.47	9.44	0.37	18.88%	20.06%	14.15%	N/A
MLYS Mineralys Therapeutics	-$154.65M	-$2.05	N/A	N/A	N/A	N/A	-27.92%	-26.98%	8/12/2026 (Estimated)
RAPP Rapport Therapeutics	-$111.48M	-$2.60	N/A	N/A	N/A	N/A	-29.02%	-27.37%	N/A

Latest CRMD, MLYS, HRMY, and RAPP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CRMD CorMedix	$0.26	N/A	N/A	N/A	$96.04 million	N/A
8/12/2026	Q2 2026	MLYS Mineralys Therapeutics	-$0.5486	N/A	N/A	N/A	N/A	N/A
8/5/2026	Q2 2026	RAPP Rapport Therapeutics	-$1.12	-$1.19	-$0.07	-$1.19	$2.22 million	N/A
8/4/2026	Q2 2026	HRMY Harmony Biosciences	$0.9560	$1.28	+$0.3240	$1.28	$250.77 million	$261.28 million
5/14/2026	Q1 2026	CRMD CorMedix	$0.35	$0.43	+$0.08	$0.43	$104.96 million	$127.43 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRMD CorMedix	0.33	2.97	2.74
HRMY Harmony Biosciences	0.13	3.48	3.56
MLYS Mineralys Therapeutics	N/A	44.33	44.33
RAPP Rapport Therapeutics	N/A	15.72	27.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRMD CorMedix	34.18%
HRMY Harmony Biosciences	86.23%
MLYS Mineralys Therapeutics	84.46%
RAPP Rapport Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
CRMD CorMedix	3.50%
HRMY Harmony Biosciences	11.00%
MLYS Mineralys Therapeutics	18.94%
RAPP Rapport Therapeutics	12.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRMD CorMedix	30	78.45 million	75.71 million	Optionable
HRMY Harmony Biosciences	200	58.24 million	51.83 million	Optionable
MLYS Mineralys Therapeutics	28	82.50 million	66.87 million	Optionable
RAPP Rapport Therapeutics	N/A	47.98 million	41.86 million	N/A

CRMD, MLYS, HRMY, and RAPP Headlines

Recent News About These Companies

Rapport Therapeutics (NASDAQ:RAPP) Downgraded by Wall Street Zen to Sell

August 8 at 1:49 AM | americanbankingnews.com

Rapport Therapeutics (NASDAQ:RAPP) Rating Lowered to Sell at Wall Street Zen

August 8 at 1:47 AM | marketbeat.com

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Average Rating of "Moderate Buy" by Brokerages

August 7 at 6:13 AM | marketbeat.com

BTIG Research Reiterates "Buy" Rating for Rapport Therapeutics (NASDAQ:RAPP)

August 7 at 1:30 AM | americanbankingnews.com

Rapport Therapeutics (NASDAQ:RAPP) Reaches New 52-Week High - Here's What Happened

August 6 at 11:40 AM | marketbeat.com

Rapport Therapeutics: Advancing Phase 3 Epilepsy Pipeline and De-Risked Development Path Underpins Buy Rating

August 6 at 7:11 AM | tipranks.com

Rapport Therapeutics (NASDAQ:RAPP) Announces Earnings Results

August 5 at 4:10 PM | marketbeat.com

Rapport Therapeutics' (RAPP) "Buy" Rating Reiterated at BTIG Research

August 5 at 2:47 PM | marketbeat.com

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

August 5 at 7:37 AM | tmcnet.com

Abraham Ceesay Sells 2,210 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock

July 30, 2026 | insidertrades.com

Rapport Therapeutics (RAPP) to Post Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

William Blair Initiates Coverage on Rapport Therapeutics (NASDAQ:RAPP)

July 30, 2026 | americanbankingnews.com

Rapport Therapeutics (NASDAQ:RAPP) CEO Sells $93,063.10 in Stock

July 29, 2026 | marketbeat.com

Rapport Therapeutics (NASDAQ:RAPP) Hits New 52-Week High - Here's Why

July 28, 2026 | marketbeat.com

Rapport Therapeutics (NASDAQ:RAPP) Earns Outperform Rating from Analysts at William Blair

July 28, 2026 | marketbeat.com

Siren L.L.C. Lowers Stock Holdings in Rapport Therapeutics, Inc. $RAPP

July 24, 2026 | marketbeat.com

Rapport Therapeutics (NASDAQ:RAPP) Hits New 12-Month High - Should You Buy?

July 20, 2026 | marketbeat.com

Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 5.4% - Time to Buy?

July 17, 2026 | marketbeat.com

Rapport Therapeutics' (RAPP) Buy Rating Reaffirmed at BTIG Research

July 16, 2026 | marketbeat.com

Candriam S.C.A. Invests $5.82 Million in Rapport Therapeutics, Inc. $RAPP

July 14, 2026 | marketbeat.com

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Consensus Recommendation of "Moderate Buy" by Brokerages

July 13, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRMD, MLYS, HRMY, and RAPP Company Descriptions

CorMedix NASDAQ:CRMD

$7.44 -0.07 (-0.93%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$7.45 +0.01 (+0.13%)

As of 08/7/2026 07:37 PM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Harmony Biosciences NASDAQ:HRMY

$38.41 -0.34 (-0.88%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$38.65 +0.24 (+0.62%)

As of 08/7/2026 07:34 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Mineralys Therapeutics NASDAQ:MLYS

$27.35 +0.36 (+1.33%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$27.33 -0.02 (-0.07%)

As of 08/7/2026 07:34 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Rapport Therapeutics NASDAQ:RAPP

$45.49 -0.86 (-1.86%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$45.50 +0.01 (+0.02%)

As of 08/7/2026 07:34 PM Eastern

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRMD, MLYS, HRMY, and RAPP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRMD, MLYS, HRMY, and RAPP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRMD, MLYS, HRMY, and RAPP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRMD, MLYS, HRMY, and RAPP Company Descriptions

CorMedix NASDAQ:CRMD

Harmony Biosciences NASDAQ:HRMY

Mineralys Therapeutics NASDAQ:MLYS

Rapport Therapeutics NASDAQ:RAPP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRMD, MLYS, HRMY, and RAPP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRMD, MLYS, HRMY, and RAPP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRMD, MLYS, HRMY, and RAPP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRMD, MLYS, HRMY, and RAPP Company Descriptions

CorMedix NASDAQ:CRMD

Harmony Biosciences NASDAQ:HRMY

Mineralys Therapeutics NASDAQ:MLYS

Rapport Therapeutics NASDAQ:RAPP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools